Related Experiment Video
Updated: Aug 7, 2025

Refined Murine Model of Idiopathic Pulmonary Fibrosis
Published on: June 17, 2025
Moving senolytics closer to the clinic in IPF
Daniel Kramer1, Gautam George1, Ross Summer1
1Sidney Kimmel Medical College at Thomas Jefferson University, USA; The Jane and Leonard Korman Respiratory Institute at Thomas Jefferson University, USA.
No abstract available in PubMed .
Related Concept Videos
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Drugs for Treatment of Constipation-Predominant IBS
Peripheral Artery Disease III: Interprofessional Care
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...

